SCHEDULE: Invus Group Discloses 6.3% Stake in Bicycle Therapeutics

Raymond Debbane and affiliated entities, including Invus Public Equities, have disclosed a combined 6.3% beneficial ownership stake in Bicycle Therapeutics plc.

Summary

• Raymond Debbane, through affiliated entities including Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP, has reported beneficial ownership of 3,149,049 Ordinary Shares of Bicycle Therapeutics plc.
• This aggregate ownership represents 6.3% of the company's outstanding Ordinary Shares.
• Invus Public Equities, L.P. directly holds 2,719,707 American Depositary Shares (ADSs), which represent 5.4% of the class.
• Avicenna Life Sci Master Fund LP directly holds 429,342 ADSs, representing 0.9% of the class.
• The calculation of ownership percentage is based on 49,929,952 Ordinary Shares outstanding as of October 27, 2025, as reported by Bicycle Therapeutics plc in its Form 10-Q.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake by a reputable investor group can be interpreted as a vote of confidence in Bicycle Therapeutics' potential, without indicating any immediate operational changes.

Positives

• Increased institutional ownership by a notable investment group, which can signal confidence in the company's long-term prospects.
• The filing explicitly states that the acquisition is not for the purpose of changing or influencing control, suggesting a passive investment stance.

Future Outlook

This filing does not contain forward-looking statements or guidance from Bicycle Therapeutics plc, as it is a disclosure of beneficial ownership by an external entity.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are common disclosures in the biotechnology sector, where investment firms often take significant stakes in promising companies. The disclosure of a new 5%+ stake by a group associated with Raymond Debbane, a seasoned investor, could draw attention to Bicycle Therapeutics within the broader biotech investment community.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive signal, potentially leading to increased investor confidence and demand for the stock.
• The company's management might see this as validation of their strategy and a stable long-term investor base.

Key Dates

Recommendation

A seasoned investor would note the significant institutional interest from the Invus group, which could be a positive indicator. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It suggests a 'hold' as it confirms institutional confidence without providing new catalysts for immediate price movement, beyond the initial market reaction to the ownership disclosure itself.

Keywords

Bicycle Therapeutics plc, Invus Public Equities, Raymond Debbane, Beneficial Ownership, Schedule 13G, Biotechnology, ADSs, Institutional Investment